Evidence map›Paper›PMID 40675147›Full record

ArticleCell reports methods2025

CUT&Tag and DiBioCUT&Tag enable investigation of the AT-rich epigenome of Plasmodium falciparum from low-input samples.

Jonas Gockel, Gala Ramón-Zamorano, Jessica Kimmel, Tobias Spielmann, Richárd Bártfai

Abstract read
In one paragraph

Article in Cell reports methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jonas GockelDepartment of Molecular Biology, Radboud University, 6525GA Nijmegen, the Netherlands.
Gala Ramón-ZamoranoDepartment of Molecular Biology, Radboud University, 6525GA Nijmegen, the Netherlands; Pathogen Section, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.
Jessica KimmelPathogen Section, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.
Tobias SpielmannPathogen Section, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany.
Richárd BártfaiDepartment of Molecular Biology, Radboud University, 6525GA Nijmegen, the Netherlands. Electronic address: r.bartfai@science.ru.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phenotypic variation between malaria parasites is a major contributor to the pathogen's success, facilitated by heritable yet dynamic changes in (hetero)chromatin structure. Currently, the chromatin landscape is mostly profiled by chromatin immunoprecipitation sequencing (ChIP-seq), which has several drawbacks: (1) GC-content-related artifacts, (2) substantial material requirement, and (3) a labor-intensive protocol. To overcome these limitations, we adapted cleavage under targets and tagmentation (CUT&Tag) to Plasmodium falciparum. Despite the AT richness of the genome, CUT&Tag results in reproducible heterochromatin profiles concordant with ChIP-seq data while using as little as 10,000 nuclei or crude parasite isolates. We also developed DiBioCUT&Tag, a method utilizing dimerization-induced recruitment of biotin ligase for proximity labeling of core chromatin components during the binding of regulatory proteins followed by anti-biotin CUT&Tag. These methods hence provide substantially improved means for genome-wide profiling of chromatin-associated proteins from low-input samples in the malaria parasite and potentially beyond.

Indexed as

EpigenomePlasmodium falciparumChromatinChromatin Immunoprecipitation SequencingHumansChromatinCenH3CP: geneticsCUT&TagDiBioCUT&Tagepigenomic profilingheterochromatinPlasmodium falciparum

Identifiers

PMID40675147
PMCPMC12461585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.